New Therapies for Advanced Prostate Cancer

 

 

As part of ESMO's continuous commitment to offering beneficial educational material relevant to your work and practice in order to receive your certificate, please complete the Evaluation Survey, which will take approximately 5 minutes. Please indicate which rating reflects your answer.

Questions marked with are required.

1. Did your undertaking of this E-Learning module allow you to review emerging therapies for advanced prostate cancer? (1-not at all; 5-a lot)

2. Did your undertaking of this E-Learning module allow you to understand a role and safety profile of immunotherapy, androgen receptor targeting drugs, novel hormonal therapies, and bone targeting drugs in the management of advanced prostate cancer? (1-not at all; 5-a lot)

3. Did your undertaking of this E-Learning module allow you to understand the clinical impact and potentials of results achieved within clinical studies that evaluated novel therapies in patients with advanced prostate cancer? (1-not at all; 5-a lot)

4. Please, provide your overall rating of the quality of the education offered by this E-Learning module. (1-poor; 5-excellent)

5. How would you rate the interactivity level offered in the E-Learning material? (1-poor; 5-excellent)

6. Was the information useful and relevant to your work and practice? (1-not at all; 5-completely)

7. Was the information useful and relevant to your work and practice? (1-not at all; 5-absolutely)

8. If you would like to add your personal comments or make suggestions to improve future ESMO E-Learning material, please write in the box below: